Reliability of classifying multiple sclerosis disease activity using magnetic resonance imaging in a multiple sclerosis clinic

JAMA Neurology

Volumn 70, Issue 3, 2013, Pages 338-344

  Altay, Ebru Erbayat ^a   Fisher, Elizabeth ^d   Jones, Stephen E ^c   Hara Cleaver, Claire ^b   Lee, Jar Chi ^e   Rudick, Richard A ^a  

^a Department of Pediatric Neurology   (United States)

^b Imaging Institute   (United States)

^c Departments of Biomedical Engineering   (United States)

^d Quantitative Health Sciences ^*  (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM PENTETATE;

ADULT; ARTICLE; COMPUTER PROGRAM; CONTRAST ENHANCEMENT; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DRUG RESPONSE; FEMALE; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; INTERRATER RELIABILITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROIMAGING; NEUROLOGIST; NEURORADIOLOGIST; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; NURSE PRACTITIONER; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RADIOLOGIST; REPRODUCIBILITY; RESIDENT;

EID: 84874836307     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/2013.jamaneurol.211     Document Type: Article

References (28)

1. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292302.
2. Sicotte NL. Magnetic resonance imaging in multiple sclerosis: the role of conventional imaging. Neurol Clin. 2011;29(2):343-356.
3. Barkhof F, Filippi M, Miller DH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain. 1997; 120(pt 11):2059-2069.
4. O'Riordan JI, Thompson AJ, Kingsley DP, et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS: a 10-year follow-up. Brain. 1998; 121(pt 3):495-503.
5. Fisher E, Rudick RA, Simon JH, et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology. 2002;59(9):1412-1420.
6. Miller DH. Biomarkers and surrogate outcomes in neurodegenerative disease: lessons from multiple sclerosis. NeuroRx. 2004;1(2):284-294.
7. Sormani MP, Bonzano L, Roccatagliata L, Cutter GR, Mancardi GL, Bruzzi P. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann Neurol. 2009;65(3):268-275.
8. Sormani MP, Bonzano L, Roccatagliata L, Mancardi GL, Uccelli A, Bruzzi P. Surrogate endpoints for EDSS worsening in multiple sclerosis: a meta-analytic approach. Neurology. 2010;75(4):302-309.
9. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444-1452.
10. Barkhof F, Filippi M, van Waesberghe JH, et al. Improving interobserver variation in reporting gadolinium-enhanced MRI lesions in multiple sclerosis. Neurology. 1997;49(6):1682-1688.
11. Filippi M, van Waesberghe JH, Horsfield MA, et al. Interscanner variation in brain MRI lesion load measurements in MS: implications for clinical trials. Neurology. 1997;49(2):371-377.
12. Filippi M, Horsfield MA, Rovaris M, et al. Intraobserver and interobserver variability in schemes for estimating volume of brain lesions on MR images in multiple sclerosis. AJNR Am J Neuroradiol. 1998;19(2):239-244.
13. Molyneux PD, Miller DH, Filippi M, et al. Visual analysis of serial T2-weighted MRI in multiple sclerosis: intraand interobserver reproducibility. Neuroradiology. 1999;41(12):882-888.
14. Rudick RA, Rani MR, Xu Y, et al. Excessive biologic response to IFN is associated with poor treatment response in patients with multiple sclerosis. PLoS One. 2011;6(5):e19262.
15. Filippi M, Horsfield MA, Tofts PS, Barkhof F, Thompson AJ, Miller DH. Quantitative assessment of MRI lesion load in monitoring the evolution of multiple sclerosis. Brain. 1995;118(pt 6):1601-1612.
16. Filippi M, Paty DW, Kappos L, et al. Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow-up study. Neurology. 1995;45(2):255-260.
17. Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med. 2002;346(3):158-164.
18. Filippi M, Barkhof F, Bressi S, Yousry TA, Miller DH. Inter-rater variability in reporting enhancing lesions present on standard and triple dose gadolinium scans of patients with multiple sclerosis. Mult Scler. 1997;3(4):226-230.
19. Rudick RA, Lee JC, Simon J, Ransohoff RM, Fisher E. Defining interferon beta response status in multiple sclerosis patients. Ann Neurol. 2004;56(4):548555.
20. Río J, Rovira A, Tintoré M, et al. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients. Mult Scler. 2008;14(4):479-484.
21. Durelli L, Barbero P, Bergui M, et al Italian Multiple Sclerosis Study Group. MRI activity and neutralising antibody as predictors of response to interferon beta treatment in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2008; 79(6):646-651.
22. Rudick RA, Polman CH. Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis. Lancet Neurol. 2009;8(6):545-559.
23. Prosperini L, Gallo V, Petsas N, Borriello G, Pozzilli C. One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis. Eur J Neurol. 2009; 16(11):1202-1209.
24. Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009;8(3):254-260.
25. Giovannoni G, Cook S, Rammohan K, et al; CLARITY study group. Sustained diseaseactivity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Lancet Neurol. 2011;10(4):329-337.
26. Giovannoni G, Comi G, Cook S, et al CLARITY Study Group. A placebocontrolled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):416-426.
27. Kappos L, Radue EW, O'Connor P, et al FREEDOMS Study Group. A placebocontrolled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387-401.
28. Simon JH, Li D, Traboulsee A, et al. Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines. AJNR Am J Neuroradiol. 2006;27(2):455-461.